This paratope-specific antibody binds specifically to cemiplimab.
No reaction with free human PD-1 or cemiplimab in complex with PD-1.
Used to measure free cemiplimab in patient samples.
Recommended antibody pair for pharmacokinetic (PK) assay: CABT-ZB1156 - CABT-ZB1158.
Summary
Specifications
Antibody Isotype
Fab
Clone
AbD41947ad
Immunogen
Cemiplimab
Conjugate
Unconjugated
Applications
Application Notes
Suitable for PK bridging ELISA. We recommend the following for sandwich ELISA (Capture - Detection): CABT-ZB1156 - CABT-ZB1158 Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.
General Notes
We recommend the following antibody pair to develop a pharmacokinetic (PK) bridging assay to measure free drug: CABT-ZB1156 - CABT-ZB1158. CABT-ZB1156 is recommended for use as a capture antibody when paired with CABT-ZB1158. Cemiplimab (Libtayo) is a fully human IgG4 monoclonal antibody. It is approved for treating certain types of cutaneous squamous cell carcinoma and non-small cell lung cancer. The drug works by inhibiting the programmed cell death protein 1 (PD-1) receptor, thereby enhancing T cell responses against tumor cells and promoting anti-tumor activity.
Target
Alternative Names
Cemiplimab; Libtayo
Citations
Publication ()
Have you cited CABT-ZB1156 in a publication? Let us know and earn a reward for your research.
My Review for Human Anti-Cemiplimab monoclonal antibody, clone AbD41947ad
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
